Skip to main content

Table 1 Clinical characteristics and FIGO stage distribution of 72 cervical cancer patients with extensive PET-positive pelvic, para-aortic, and/or supraclavicula node disease treated with curative-intent PET-guided extended-field chemo-IMRT/3D-brachytherapy

From: Patterns of failure after use of 18F-FDG PET/CT in integration of extended-field chemo-IMRT and 3D-brachytherapy plannings for advanced cervical cancers with extensive lymph node metastases

PET-based staging N1 (multiple pelvic-only nodes) M1 (para-aortic and/or supraclavicular nodes without visceral metastasis)
The PET-detected highest level of lymph node involvement pelvic para-aortic supraclavicular
No. of Patients 26 31 15
Age at diagnosis, years
 Median 50.9 53.1 52.5
 Range 32.3–73.6 29.8–73.8 36.9–68.7
Tumor histology (%)
 Squamous cell carcinoma 26 (100) 28 (90.3) 12 (80.0)
 Adenocarcinoma 0 (0) 2 (6.5) 3 (20)
 Adenosquamous 0 (0) 1 (3.2) 0 (0)
FIGO clinical stage
 IA2-IB2 5 (19.2) 8 (25.8) 4 (26.7)
 IIA-IIB 18 (69.2) 18 (58.1) 9 (60.0)
 IIIA-IIIB 3 (11.5) 3 (9.7) 1 (6.7)
 IVA 0 (0) 2 (6.5) 1 (6.7)
  1. Abbreviations: FIGO International Federation of Gynecology and Obsterics